Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ModeX multispecific influenza antibody
- Development stage
- Preclinical
- Lead developer
- ModeX Therapeutics
- Modality
- Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
ModeX Therapeutics, a subsidiary of OPKO Health, is developing a multispecific antibody for the treatment and prevention of influenza. Built on the proprietary MSTAR (Multispecific Trans-Antigen Receptor) platform, this therapeutic candidate incorporates multiple independent binding sites into a single molecule to target various conserved epitopes of the influenza virus. This design aims to provide broad-spectrum neutralization against a wide range of seasonal and pandemic influenza strains, including those that may emerge in the future. The program, which is currently in preclinical development, has received funding from BARDA and is exploring both protein and gene-based delivery methods.
- Other names
- ModeX influenza programMSTAR influenza antibody
02
Targets
HA (Hemagglutinin)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)M2e (Influenza A matrix protein 2 ectodomain)Neuraminidase
Beyond the preview
Go deeper on ModeX multispecific influenza antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ModeX multispecific influenza antibody.